The Law Firm of Goldman Scarlato & Karon, P.C. Announces Class Action Lawsuit Against NPS Pharmaceuticals, Inc.CONSHOHOCKEN, Pa. -- Goldman Scarlato & Karon, P.C., a law firm with offices in Pennsylvania and Ohio, announces that a lawsuit has been filed in the United States District Court for the District of Utah The United States District Court for the District of Utah is the Federal district court whose jurisdiction is the state of Utah. The court is based in Salt Lake City. The United States Attorney's Office for the District of Utah , on behalf of persons who purchased or otherwise acquired publicly traded securities of NPS NPS National Park Service NPS Naval Postgraduate School NPS Net Promoter Score (customer management) NPS Non-Point Source pollution NPS Native Plant Society NPS Norfolk Public Schools (Virginia) Pharmaceuticals, Inc. ("NPS" or the "Company") (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :NPSP NPSP New Parent Support Program NPSP National Polio Surveillance Project (India) NPSP Native Plant Stewardship Program (Washington Native Plant Society) NPSP Nonparametric Statistical Package ) between August 10, 2005 and May 2, 2006, inclusive, (the "Class Period"). The lawsuit was filed against NPS and certain officers and directors ("Defendants"). If you are a member of this class and wish to view a copy of a complaint and join this class action, please e-mail us at info@gsk-law.com and request a copy of the complaint and a plaintiff certification. If you are a member of the Class, you may move the Court no later than September 11, 2006 to serve as a lead plaintiff for the Class. Any member of the purported class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. However, if you choose to remain an absent class member, unless and until a class is certified, you are not represented by counsel. The complaint alleges that Defendants violated the federal securities laws by issuing a series of materially false statements concerning the potential success of PREOS PREOS Prediction of Performance & Range for Electro-Optical Systems , the Company's full-length human parathyroid hormone parathyroid hormone or parathormone, a hormone secreted by the parathyroid glands that regulates the metabolism of calcium and phosphate in the body. , a drug candidate treatment for osteoporosis osteoporosis (ŏs'tēō'pərō`sĭs), disorder in which the normal replenishment of old bone tissue is severely disrupted, resulting in weakened bones and increased risk of fracture; osteopenia . Specifically, Defendants concealed: (1) results of the PaTH study evidenced that PEROS was not different from Fosamax in both bone density and fracture results; (2) there was a very small market for this type of drug; (3) a major study concluded that more studies would be needed to determine efficacy; and, (4) PREOS could not be prescribed for broader fracture uses. If you bought NPS securities between August 10, 2005 and May 2, 2006, inclusive, and would like to obtain information about the lawsuit, then you are invited to call (888) 753-2796 to speak with an advisor. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion